Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
Eli Lilly reported stronger-than-expected Q3 2026 results, driven by resilient demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company raised its full-year sales outlook, citing regulatory progress and growth in the metabolic health segment. Lilly's revenue climbed on surging sales of these two blockbuster drugs.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly's sales outlook for 2026 was raised due to strong demand for Mounjaro and Zepbound.
- ✓ The company's revenue climbed on surging sales of Mounjaro and Zepbound in Q3 2026.
- ✓ Eli Lilly reported stronger-than-expected third-quarter 2026 results.
What changed
Eli Lilly raised its 2026 sales outlook due to stronger-than-expected Q3 results fueled by demand for Mounjaro and Zepbound.
Live updates
-
Eli Lilly raises sales outlook on strong Zepbound and Mounjaro demand
Eli Lilly reported stronger-than-expected Q3 2026 results, driven by resilient demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company raised its full-year sales outlook, citing regulatory progress and growth in the metabolic health segment. Lilly's revenue climbed on surging sales of these two blockbuster drugs.
Why it matters
Eli Lilly's performance is significant in the pharmaceutical industry, particularly in the areas of diabetes and obesity treatment. The company's success with Mounjaro and Zepbound has positioned it as a leader in the metabolic health market. This update provides insight into Lilly's financial health and its ability to innovate and meet demand in key therapeutic areas.
What is confirmed
- Eli Lilly's sales outlook for 2026 was raised due to strong demand for Mounjaro and Zepbound.
- The company's revenue climbed on surging sales of Mounjaro and Zepbound in Q3 2026.
- Eli Lilly reported stronger-than-expected third-quarter 2026 results.
What to watch next
- Lilly's regulatory progress and future product launches
- Q4 2026 sales performance and full-year guidance update
- Competitor responses to Lilly's success in the obesity and diabetes markets
confidence 100%Sources used for this update (8)
- CNBC — Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
- Eli Lilly — Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
- Yahoo Finance — Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
- Bloomberg — Lilly Raises Sales Guidance, Widening Its Lead in Obesity Market
- WSJ — Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
- www.cnbc.com — Eli Lilly (LLY) earnings Q3 2026 - CNBC
- finance.yahoo.com — Eli Lilly Raises 2026 Sales Outlook on Mounjaro, Zepbound ...
- global.svn.com — Eli Lilly Raises Sales Outlook on Zepbound, Mounjaro Demand
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community